24
19
1
49
2
2
2c
1b
1d
18
39
63
1d
2 29
1d
25
Shanthi Sivendran, MD, MSCR
88
63
Clinical Associate Professor of Medicine (Hematology-Oncology)
7
5f
Department: Medicine
4
1
b
1d
46
Contact information
50
4
3
3
3
2
4
b
1f
50
Ann B. Barshinger Cancer Institute
34 2102 Harrisburg Pike
Lancaster, PA 17601
26
34 2102 Harrisburg Pike
Lancaster, PA 17601
35
f
13
Education:
21 7 BS 21 (Science and Biology ) c
51 Pennsylvania State University, Schreyers Honors College , 1999.
21 7 MD 15 (Medicine) c
49 University of College Dublin School of Medicine , 2004.
21 9 MSCR 2b (Science and Clinical Research ) c
41 Mount Sinai School of Medicine (NIH K30), 2011.
21 7 MS 25 (Business Administration ) c
37 Isenberg School of Management , 2021.
c
3
3
3
3
8d
Permanent link21 7 BS 21 (Science and Biology ) c
51 Pennsylvania State University, Schreyers Honors College , 1999.
21 7 MD 15 (Medicine) c
49 University of College Dublin School of Medicine , 2004.
21 9 MSCR 2b (Science and Clinical Research ) c
41 Mount Sinai School of Medicine (NIH K30), 2011.
21 7 MS 25 (Business Administration ) c
37 Isenberg School of Management , 2021.
c
2 29
21
1e
1d
24
2b
29
27
23
184 Newport K, Sivendran S. : Including the Oncologist in Palliative Oncology: A Response to Nature of Discussions about Systemic Therapy Discontinuation or Hospice among Patients, Families, and Palliative Care Clinicians during Care for Incurable Cancer: A Qualitative Study. J Palliat Med. 23(4): 451-452, Apr 2020.
146 McNaughton CH, Horst M, Gehron E, Sivendran S, Nguyen J, Holliday R, Newport K. : Patterns of Support Service, Emergency Department and Hospital Utilization in Patients with Advanced Cancer: A Descriptive Study. J Palliat Care. 35(1): 34-39, Jan 2020.
cf Finlay E, Newport K, Sivendran S, Kilpatrick L, Owens M, Buss MK : Models of Outpatient Palliative Care Clinics for Patients With Cancer. J Oncol Pract 2 2e 15(4): 187-193, Apr 2019.
10b Sivendran S, Jenkins S, Svetec S, Horst M, Newport K,Yost KJ, Yang M.: Illness Understanding of Oncology Patients in a Community-Based Cancer Institute. J Oncol Prac. 13(9): e800-e808. Sep 2017.
f3 Wyluda E, Newport K, Sauder M, Sivendran S.: Safety and efficacy of vandetanib in the treatment of medullary thyroid cancer. Journal of Signs and Symptoms 3(2), Aug 2016.
af Sivendran S, Galsky MD.: Adverse event reporting in oncology clinical trials - lost in translation? Expert Opin Drug Saf 2 2c 15(7): 893-6, Jul 2016.
129 Sivendran S, Holliday R, Guittar R, Cox C, Newport K: The impact of a nurse practitioner-led symptom clinic on emergency department use in cancer patients. Journal of Community and Supportive Oncology 14(6): 268-272, 2016.
e3 Perkins SH, Stensland KD, Galsky MD, Sivendran S.: Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies. Trials 28 16: 341, Aug 2015.
151 Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Agarwal N, Galsky MD.: Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol. 9(3): 195-204, Sep 2014.
2c
7
1d
1f
Selected Publications
149 Sivendran S, Lynch S, McNaughton C, Wong R, Svetec S, Moore JH, Holliday R, Oyer RA, Newport K.: Anticancer Therapy at the End of Life: Lessons From a Community Cancer Institute. J Palliat Care. 36(2): 87-92, Apr 2021 Notes: doi: 10.1177/0825859719851484.184 Newport K, Sivendran S. : Including the Oncologist in Palliative Oncology: A Response to Nature of Discussions about Systemic Therapy Discontinuation or Hospice among Patients, Families, and Palliative Care Clinicians during Care for Incurable Cancer: A Qualitative Study. J Palliat Med. 23(4): 451-452, Apr 2020.
146 McNaughton CH, Horst M, Gehron E, Sivendran S, Nguyen J, Holliday R, Newport K. : Patterns of Support Service, Emergency Department and Hospital Utilization in Patients with Advanced Cancer: A Descriptive Study. J Palliat Care. 35(1): 34-39, Jan 2020.
cf Finlay E, Newport K, Sivendran S, Kilpatrick L, Owens M, Buss MK : Models of Outpatient Palliative Care Clinics for Patients With Cancer. J Oncol Pract 2 2e 15(4): 187-193, Apr 2019.
10b Sivendran S, Jenkins S, Svetec S, Horst M, Newport K,Yost KJ, Yang M.: Illness Understanding of Oncology Patients in a Community-Based Cancer Institute. J Oncol Prac. 13(9): e800-e808. Sep 2017.
f3 Wyluda E, Newport K, Sauder M, Sivendran S.: Safety and efficacy of vandetanib in the treatment of medullary thyroid cancer. Journal of Signs and Symptoms 3(2), Aug 2016.
af Sivendran S, Galsky MD.: Adverse event reporting in oncology clinical trials - lost in translation? Expert Opin Drug Saf 2 2c 15(7): 893-6, Jul 2016.
129 Sivendran S, Holliday R, Guittar R, Cox C, Newport K: The impact of a nurse practitioner-led symptom clinic on emergency department use in cancer patients. Journal of Community and Supportive Oncology 14(6): 268-272, 2016.
e3 Perkins SH, Stensland KD, Galsky MD, Sivendran S.: Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies. Trials 28 16: 341, Aug 2015.
151 Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Agarwal N, Galsky MD.: Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol. 9(3): 195-204, Sep 2014.
2c
44
23
Back to Top
1b
1d
18